A pyridoxal-phosphate protein that requires potassium for activity . In the proteobacterium Acinetobacter baumannii, this enzyme is cotranscribed with the neighbouring ddc gene that also encodes EC 4.1.1.86, diaminobutyrate decarboxylase. Differs from EC 2.6.1.46, diaminobutyrate---pyruvate transaminase, which has pyruvate as the amino-group acceptor. This is the first enzyme in the ectoine-biosynthesis pathway, the other enzymes involved being EC 2.3.1.178, diaminobutyrate acetyltransferase and EC 4.2.1.108, ectoine synthase [3,4].
Involved in the formation of 1,3-diaminopropane in Haemophilus influenzae and Acinetobacter baumannii. A product of the ddc gene that also encodes L-2,4-diaminobutyrate decarboxylase in Acinetobacter baumannii. Differs from EC 2.6.1.46 diaminobutyrate-pyruvate transaminase, which has pyruvate as the amino-group acceptor
A pyridoxal-phosphate protein that requires potassium for activity [4]. In the proteobacterium Acinetobacter baumannii, this enzyme is cotranscribed with the neighbouring ddc gene that also encodes EC 4.1.1.86, diaminobutyrate decarboxylase. Differs from EC 2.6.1.46, diaminobutyrate---pyruvate transaminase, which has pyruvate as the amino-group acceptor. This is the first enzyme in the ectoine-biosynthesis pathway, the other enzymes involved being EC 2.3.1.178, diaminobutyrate acetyltransferase and EC 4.2.1.108, ectoine synthase [3,4].
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
production of ectoine in Escherichia coli. The Escherichia coli regulatory protein AraC is engineered to recognize ectoine as it snon-natural effector and to activate transcription upon ectoine binding. The ectoine biosynthetic cluster from Halomonas elongata is cloned into Escherichia coli. By engineering the rate-limiting enzyme L-2,4-diaminobutyric acid aminotransferase EctB, ectoine production and the specific activityof the EctB mutant are increased
production of ectoine in Escherichia coli. The Escherichia coli regulatory protein AraC is engineered to recognize ectoine as it snon-natural effector and to activate transcription upon ectoine binding. The ectoine biosynthetic cluster from Halomonas elongata is cloned into Escherichia coli. By engineering the rate-limiting enzyme L-2,4-diaminobutyric acid aminotransferase EctB, ectoine production and the specific activityof the EctB mutant are increased
Identification and analysis of a gene encoding L-2,4-diaminobutyrate:2-ketoglutarate 4-aminotransferase involved in the 1,3-diaminopropane production pathway in Acinetobacter baumannii
HOME
login
history
all enzymes
BRENDA home
History
2.6.1.76 diaminobutyrate-2-oxoglutarate transaminase
more
top
Information
